Language selection

Search

Patent 1038759 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1038759
(21) Application Number: 1038759
(54) English Title: MIXTURES OF CEPHALOSPORIN AND PENICILLIN TYPE ANTIBIOTICS
(54) French Title: MELANGES D'ANTIBIOTIQUES DU TYPE CEPHALOSPORINE ET PENICILLINE
Status: Term Expired - Post Grant Beyond Limit
Bibliographic Data
Abstracts

English Abstract


ANTIBACTERIAL COMPOSITION FOR ANIMALS
Abstract of the Disclosure:
An antibacterial composition for animals comprising
cephalosporin compound of the formula:
<IMG>
wherein R1 is a substituted or unsubstituted heterocyclic
group, or its salt and a penicillin compound of the formula:
<IMG>
wherein R2 is an acyl group, or its salt, said composition
having synergism between the cephalosporin compound and the
penicillin compound and being useful for preventing and treat-
ing diseases induced by pathogenic bacteria in animals.
- 1 -


Claims

Note: Claims are shown in the official language in which they were submitted.


The embodiments of the invention in which an exclusive property
or privilege is claimed are defined as follows:-
1. An antibacterial composition for animals comprising
a cephalosporin compound of the formula:
<IMG>
wherein R1 is a substituted or unsubstituted 5- or 6-membered
heterocyclic group including at least one nitrogen atom or a
salt thereof and a penicillin compound of the formula:
<IMG>
wherein R2 is an acyl group selected from the group consisting
of heterocyclic carbonyl, phenylacetyl, alkanoyl of 2 to 8
carbon atoms and alkanoyl of 2 to 8 carbon atoms, said acyl
group being substituted or unsubstituted or a salt thereof.
2. The antibacterial composition for animals according
to claim 1, wherein said cephalosporin compound and said
penicillin compound are present in a ratio of 1:1 to 1:10,
by weight.
3. The antibacterial composition for animals according
to claim 1 or 2, wherein R1 is a member selected from the group
consisting of 1,3,4-thiadiazol-2-yl, 5-methyl-1,3,4-thiadiazol-
2-yl, 5-methyl-1,3,4-oxadiazol-2-yl, 1,2,3-triazol-4-yl, 1-
methyl-1,3,4-triazol-2-yl, and 1-methyltetrazol-5-yl.

4. The antibacterial composition for animals according
to claim 1, wherein the cephalosporin compound is a member
selected from the group consisting of Cefazolin, 7-(tetrazol-
1-yl)acetamido-3-(1,3,4-thiadiazol-2-yl)thiomethyl-3-cephem-
4-carboxylic acid, 7-(tetrazol-1-yl)acetamido-3-(1-methyl-
tetrazol-5-yl)thiomethyl-3-cephem-4-carboxylic acid and salts
thereof.
5, The antibacterial composition according to claim 1
or 2, wherein R2 is alkanoyl or alkenoyl having 2 to 8 carbon
atoms, and is unsubstituted or substituted by amino, carboxy
or aryloxy, said aryloxy being unsubstituted or substituted
by hydroxy, halogen or nitro, a phenylacetyl wherein the
phenyl group is unsubstituted or substituted by hydroxy or
methoxy and the acetyl group is unsubstituted or substituted by
amino, carboxy or sulfo at the .alpha.-position, and a hetero-
cyclic carbonyl wherein the heterocyclic group is unsub-
stituted or substituted by a lower alkyl or aryl wherein the
aryl group is unsubstituted or substituted by halogen.
6. The antibacterial composition for animals according
to claim 1 or 2, wherein R2 is a member selected from the
group consisting of 2-pentenylcarbonyl, n-heptylcarbonyl,
caproyl, 4-amino-4-carboxybutylcarbonyl, .alpha.-phenoxybutyr
.alpha.-phenoxypropionyl, p-chlorophenoxyacetyl, phenylacetyl,
p-hydroxyphenylacetyl, .alpha.-amino-(p-hydroxyphenyl)acetyl, .alpha.-
sulfo-phenylacetyl, .alpha.-carboxyphenylacetyl, 2,6-dimethoxy-
phenylacetyl, .alpha.-amino-phenylacetyl, (5-methyl-3-phenylisoxazol-
4-yl)carbonyl, [3-(o-chlorophenyl)-5-methylisoxazol-4-yl]-
carbonyl, [3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]-
carbonyl, (5-methyl-3-phenylisoxazol-4-yl)carbonyl and [3-
(6-fluoro-2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl.
16

7. The antibacterial composition for animals according
to claim 1, wherein the penicillin compound is a member
selected from the group consisting of penicillin G, penicillin
X, penicillin F, penicillin K, 3-pentenylpenicillin, dihydro-
penicillin F, penicillin N, isopenicillin N, penicillin V,
carbenicillin, cloxacillin, dicloxacillin, oxacillin, methicillin,
propicillin, phenethicillin, ampicillin, flucloxacillin,
amoxycillin and sulbenicillin.
8. The antibacterial composition for animals according
to claim 2, wherein the cephalosporin compound is a member
selected from the group consisting of Cefazolin, 7-(tetrazol-1-
yl)acetamido-3-(1,3,4-thiadiazol-2 yl)thiomethyl-3-cephem-4-
carboxylic acid, 7-(tetrazol-1-yl)acetamido-3-(1-methyl-
tetrazol-5-yl)thiomethyl-3-cephem-4-carboxylic acid and
salts thereof; and the penicillin compound is a member
selected from the group consisting of penicillin G, penicillin
X, penicillin F, penicillin K, 3-pentenylpenicillin, dihydro-
penicillin F, penicillin N, isopenicillin M, penicillin V,
carbenicillin, cloxacillin, dichloracillin, oxacillin, methi-
cillin, propicillin, phenethicillin, ampicillin, flucloxa-
cillin, amoxycillin and sulbenicillin.
9. The antibacterial composition for animals according
to claim 1, 4 or 8, wherein the cephalosporin compound or
a salt thereof and the penicillin compound or a salt thereof
are present in a ratio of 1:1 to 1:4 by weight.
10. An antibacterial composition for animals comprising
cefazolin a salt thereof and carbenicillin or a salt thereof
in a ratio of 1:1 to 1:4 by weight.
11. An antibacterial composition for animals comprising
cefazolin or a salt thereof and cloxacillin or a salt thereof
17

in a ratio of 1:1 to 1:4 by weight.
12. An antibacterial composition for animals comprising
cefazolin or a salt thereof and dicloxacillin or a salt thereof
in a ratio of 1:1 to 1:4 by weight.
13. An antibacterial composition for animals comprising
7-(tetrazol-1-yl)acetamido-3-(1,3,4-thiadiazol-2-yl)-thio-
methyl-3-cephem-4-carboxylic acid or a salt thereof and
flucloxacillin or a salt thereof in a ratio of 1:1 to 1:4
by weight.
14. An antibacterial composition for animals comprising
7-(tetrazol-1-yl)acetamido-3-(1-methyltetrazol-5-yl)-thio-
methyl-3-cephem-4-carboxylic acid or a salt thereof and amoxy-
cillin or a salt thereof in a ratio of 1:1 to 1:4 by weight.
18

Description

Note: Descriptions are shown in the official language in which they were submitted.


~L~3~3~5~ ::
The present invention relates to ~n antibacterial
composition for animalsO More partlcularly, it relates to an
antibacterial composition comprising a cephalosporin com~ound
or it~ salt ~nd a penicillin compound or its salt.
Cephalosporin compounds an~ penicillin co~pounds-and
their salts have been known as antibiotics having a wide range
of antibacterial spectrum.
A~ the results of the extensive s-tudyings of the
pre3ent inventors~ it has been newly found ~hat some speci~
~ic cephalosporin compounds or their salts exhibit a synergis-
tic antibacterial activities by combining with some penicillin
compounds or their salts, th~t is, the combination of the ~ -
cephalosporin compounds or their salt with t'ne penicillin com-
pounds or their salts shows a strong antibacterial activity
-
against pathogenic bacteria in animals other than human,~par-
~ticularly gr~m-ne~ative bacteria such as Citrobacter and Proteus,
~against which the ceph~losporin compounds and penicillin com~
pounds show no or litt~e antibacterial activit~, when they are
u6ed each alone, and against the cephalosporin compounds- and
penicillin compounds-resistant bacteria.
- ~ An object of the present inven~ion i~ to provide an
antibacterial composition for animals comprisine a cephalo-
8porin compound or its salt an~ a penicillin compound or its
salt useful against pathogenic bacteria in animals, against
whiCh the cephalosporin compound or the penicillin compour.d
alone i3 not eff~ctive.
~ nothcr ob~ect o~ the invention is to provide an
antibacterlal composltion 40r animal~ useful a~ain~t the cephalo-
8porin co~pound- or penicillin co~pound-r~istant bacteria.
A further ob~ect OL th~ invent~on is to provide an
- 2 - ~ `

~3~7S~ :
antibacterial composition for nnimals having an excell0nt bac~
tericidal rate an~ enhanced therapeutic and preventive effects.
A still further object of the invention is to pro-
~ide an antibacterial compo~it~on u~eful for treating or pre~
venting animal disea~es induced by pathogenic bacteria, par-
ticularly ma~titi~ in cow or other animals.
These and other objects of the in~ention will be ;.
apparent from the description hereinafter.
: The antibacterial composition of the present inven~
tion comprises a combination o~ a cephalosporin compound o~
the formula~
., ~ ~' .
70 N 2 ~ ~
~_~" ~,L_-N \ ~ H2 ~-Rl .
- 1 . .-: .
- - ~OOH .
wherein ~ is a substituted or unsubstituted heterocyclic
group, or its salt and a penicillin compound of the formula~
S CH~
COOH
1-
wherein R2 is an acyl group, or its salt. . 1`
The heterocyclic group (Rl) in the above cephalo-
~porln compound (I) i~ a 5 or 6-membered heterocyclic group
including at lea~t one nitrogen atom and includes, for.e~ample.
thiadiazolyl, o~adiazolyl, thiazolyl and tetrazolyl which may
be substituted bg an alkyl group having 1 to 4 carbon atoms.
Preferred heterocyclic group i~ 1,3,4-thiadiazol-2-yl, 5-methyl-
~ 4-thiadiazol-2-yl, 5-methgl 1,3,4-oxadiazol-2-yl, 1,2,3-
triazol-4-yl, 1-methyl-1,3,4-triazol-2 yl and l-methyltetrazol-
5-yl. The tetrazolylacetamido.group at 7 position o~ cephalo-
_ ~ _
.. ..... . .. .
.. ..
. ~ , . .

~3~759
8porin compound (I) includes (tetrazol-1-yl)aoetamido and
(tetrazol-2-yl)acetamido
The ~alts of the cephalosporin compounds (I) include
~hysiologically acceptable salts, such as a metal salt (e.g.
sodium, potassium or calcium salt); ammonium salt, an amine
salt (e.g. trimethylamine, triethylamine, procaine or dibenzyl-
amine ~alt), a salt with a basic amino acid, or the like which
are a conventional salt of cephalosporin compounds.
Pre~erred examples of the cephalosporin compounds
(I) are 7-(tetrazol-l-yl)acetamido-3-(5-~ethyl~1,394-thla_
diazol-2-yl)thiomethyl-3-cephem-4-carboxylic acid (i.e.
cefazolin), j-(tetrazol-l-yl)acetamido-3-(1,3,4-thiadiazo1-
2-yl)thiomethyl-3-cephem-4-carboxylic acid (hereinafter, re-
~erred to ss ~R-10123) and 7-(tetrazol-1-yl~acetam1do-3-
methyltetrazol-5-yl)thiomethyl-3-cephem-4-carboxylic acid
(hereinafter, referrea to aæ FR-10675) and the1r salts. Among
such cephalosporir.s, cefasolin sodium is known æs~ni~ue anti-
biotics and marked world-widely.
The pen}cill1n compounds (II~ include natursl peni- ~
oillin~ and semi-synthetic penicillins. And, as ths acyl group
o~ the penicillin compounds (II), there are msntioned, ~or ex
amp-e, an alkanoyl and alkenyl ha~ing 2 to 8 carbon atoms which
may be æubstituted by amino, carbo~y or aryloxy whic~ may be
,
8ubstituted by hydroxy, halogen or nitro (e.g. 2-pentenylcarbonyl,
n-heptylcarbonyl, caproyl, 4-amino-4-carbo~ybutyryl, a-phenoxy-
butyryl, a-phenoxypropionyl or p-chlorophenoxyacetyl); a phenyl-
acetyl wherein the phenyl eroup may be substituted by hydroxy
or methoxy and the acetyl ~roup may be ~ubstituted by amino,
carboxy or 8u1~0 at the a-po8ition (e,g. phenylacetyl, p-hydroxy-
phenylacetyl, a-amino-(p-hydroxyphenyl)acetyl, a-~ulfo-phenyl
- 4
.... . . ............ . . . . . . .
,~' ' l!
. , .

759
acetyl, u-carboxy-phenyla~etyl, 2,6-dimethoxyphenylacetyl or
a~aminophenylacetyl) and a heterocyclic carbonyl wherein the
heterocyclic group may be ~ubstituted by a lower alkyl or aryl
wherein the aryl group may be ~ubstituted by a halogen (e.g.
(5-methyl-3-phenyl-isoxazol-4-yl)carbonyl7 [3-(o-chlorophenyl~
5-methylisoxazol-4~yl]carbonyl~ [3-(2,6-dichlorophenyl)-5
methyliso~azol-4~yl]carbonyl, (5-methyl-~-phenylisoxazol-4-
yl~carbonyl or [3-(6-~luoro~2-chlorophenyl)-5-methylisoxazol-
4-yl]carbonyl).
Representative examples o~ the natural penicillins
may be penicillin G, ~ X, penicillin F, penicillin
~, 3-pentenylpenicillin, dihydropenicillin F, penicillin N,
isopenicillir. ~, penicillin V, or the like. Representative ex~
amples of the semi-synthetic penicillins may be carbenicilline
: :' .
(i.e. a-carboxybenzylpenicillin), cloxacillin (i.e. ~3-(o-chloro-
phenyl)-5-methyl-4-isoxazolyl]penicillin), dicloxacillin (i.e.
~ -(296-dichlornphenyl-5-methyl-4-i~oxazolyl]penicillin), o~a-
cilline (i.e, (5-methyl-3-phenyl-4-isoxazolyl)penicillin), methi-
c~llin (i.e. (2,6 dimethoxyphenyl)penicil-in), propicillin (i.e.
a-phenoxypropylpenicillin) 9 phenethicillin (i.e. a-phenoxyethyl-
penicillin)9 ampicillin (i.e. D(-)-a-aminobenzylpenicillin),
~luclo~acillin ~i.e. [3-(6-fluoro-2-chlorophenyl)-5-methyl-4-
iso~azolyl]penicillin), sulbenicill1n (i.e. a-sulfo-phenylacet-
amidopenicillin), amoxycillin (i.e. D(-)-a-amino-(p-hydroxyphenyl)-
acetamidopenicilIin~, or the like and their ~alts. ~;
The salt~ of the pen~cillin compound~ (II) are exempli~~ied the same examples as those of cephalosporin compound (I).
Preferred combinations of the cephalosporin compound~
and the penicillin compounds are a combination of a cephalo-
~porin compound ~elected from the group consisting of cefazolin,
5 -- .
- ''
. , ,
;, .

37~ :
FR-10123 and FR-10675 and a penicillin compound selected
from the group consistin~ oL carbenicillin, cloxacillin, di-
cloxacillin, oxacillin, methicillin, propicillin, phenethi-
cillin, ampicillin, fluclo~acillin, amoxycillin and sulbeni-
~illin. The most preferr~d eombinations are ce~azolin/carbeni-
cillin, cefa7.01in/clo~acillin, cefazolin/dicloxacillin~ FR-10123/
~lucloxacil~in and ~R-10675Jamoxycillin.
- The ratio of the cephalosporin compound or its salt
and the penicillin compound or its salt in the present anti-
bacterial composition may vary with the compounds to be combined
respectively, the ~ind~ o~ the bacteria and the symptoms of the
infected animals to which the present composition i9 applied,
but may usually be in a range of 1 1 to 1 : 10 by weight, pre- ~ -
~erably 1 : i to 1 : 4 by weight. --~
... . : . .. . . .
The antibacterial composition of the present inven-
tion is useful for treætin6 and preventing diseases induced by
pathogenic bacterla in anlma~ls other than human, for instance,
poultry, domes~ic animals, pet animals, or experimental ani-
mals (e.g. chicken, turke~, duc~., quail, cow, cattle, horse, -
~ pig, hog, dog, sheep, goat, mink, canary, macaw, mouse, rat or
- rabbit).
.
~ he present antib~cterial composition may be applied
to the animals in conventional forms which the conventional
cephalosporin preparations and penicillin preparations are
a~plied to. ~or instance, it is preferably applied in a form
o~ in~ection, and for treating mastiti~ in cow or other ani-
male, it i3 preferably a~plied in a form of infusion. It may
be also be applied locally in a form of a powder or an oint-
ment. When u3ed a~ an in~ection or infusion, it may be u~ed
in admi~ture with a solid or liquid carrier or diluent .~hich
- 6 -
"

~ i3~759
i~ u~ually u~ed for the conventional antibiotic injections or
infusions. The most preferred carrier or diluent is water~
vegitable oils, ~ara~fin~ or the like. ~lhen used a~ an oint-
ment, it may be used in admixture with conventional oint~ent
bases.
The dosage o~ the pre~ent composition Jill vary with
the kinds of the cephalosporin compounds and the penicillin
, . ..
compounds and the mixed ratio thereof as well as the ~inds and ~
. , , , , ~ ,
the severity of the infection. For instance, for treating ~ov-
vine mastiti~ during lactation drying period, it may be adminis-
tered in a dose of about 200 mg/quarter.
The antibacterial activities and the preventing effec-
:
tiveness aga~nst bacteial infection of the present compositon
are illustrated by the following experimental tests in vitro and
in VlVO.
~t 1
_, ~
~ynergi~tic activity of cefazolin and cloxacillin
.. - :
against pathogen isolated from milk o~ cow suffering from mastitis
, , ~ .
i~ the inhibitory concentration test in ~itro~
In a heart infusion medium containing a prescribed
amount of cloxacillin and cefazolin sodi~n (hereinafter, re-
~erred to merely as "aefazolin" was inoculated each pathogen ~/ -
ln a concentration of about 105 cells/ml, and it was.cultured
at 375C ~or ~0 hours, and then the growth of the test micro-
or~anism3 wa~ mea~ured. The result~ are shoT~n in the follow-
ing table In the tables, the symbol "+" means that the test
microoreani~m ~rew and the symbol "-" means that the test
microor~an~sm did not erow.
- 7 -

~:3387~ :
Table_l ~Escherichia coli, strain 4U-58-2L~) .
Cloxacillin
(mcg/ml) ____l_____ . . :
5 _ _ _ _ . .
f _ _ :~
12.5 - ~ - ~ _ ::~
6.25 + + .+ _ ;
. o + _ _ L~ . ~ ~ .
:
0 0.39 0,78 1.56 -
Cefazolin ~mcg/ml)
Table 2 (Escherichia coli, strain 8-29-RB) .
,... - .
Cloxacillin
(mcg/ml) _ .
100 ~ __ _ .-
~ _ ~
~ ~ 50 : ~ ~ _ _ _
_ _ _ .
+ * r-~~~ ~ ~ I;
12.5 + + + _ _
_, ~ ..
6.25 + ~ + _ _
3.13 + + + _ ~ :
:--
O, + L~ +_ , +
. 0: .3g0.7~ 1~56 3.13
Cefazolin (mcg/ml)
~ .
: ~ .
~:
,
, ,, :
. .
,
;'. . .

10;3B759 ¦:
Table 3(Proteus mirabllis, strain 48-~2~F) :
Cloxacillin ~
(m4go/ml) _ _ _ I ; ' ~:
200 _ + _ _ _ . ~
100 + + ~__ _ , `,',,~
5o + + ~ ;
~ , }, .
+ + ~ + _ . ~
__ . ' ,~
12.5+ + + + _ ~ -:
...
6.25 + + + + _ ::~
_~ . .,:' . ,
O ,+ ,+ ~ + + . ,~ '",''
0 0.78 1.56 3.1~ 6.25 ~-
Cefa~olin (mcg/ml)
Test 2
~ ~ Synerglstic activ1ty of cefazolin and~cloxacillin
:~ against pathogen isolated from dogs suffering from diarrhea in
: the inhibitory concentration~test in vitro: : ,~
In the aame manner as described in Test 5, the test
~as~carried out with Salmonella spp.~isolated from rectum feces
;~
of diarrhea dogs. ~he results are shown i.n the following tables. .~: :
almonella t2~____ rium, strain Dl55)
Cloxacillin :~
(mcg/ml) r--~ I .
200 + _ _ I _ _
_ : ~ - _
'~.: ,100 , + +_ _ _ ; - , '~
: . 50 + ~ + + _ j
_ "
25 + + + + _ .
,. -- .,
f 12,5 ~ + I + ~ +
6.25 + + + ~ .
i ~,;
, O + + + I + ~ , .
. __ l :
0 0.20.39 0.78 1.56
Cefezolin (mcg/ml) :
,,, , ,
,; ,~",
.', _ 9 _ ~;
',, '
.'
" . , , , ~ , . .
~:
,, 1 i
,'' ,' ~ ' , ' ,
,. . . .

-~ ~~38~7S9 :-
Table 5 (~almonella enteritidi~, ~train 1892)
Cloxacillin
( ms_/m )
12.5 ~ + + +
6.25 + + + + `
~ ' . O _ __ _ . ''~'-"':'
0 0,78 1.56 3.1
Cefazolin (mcg/ml)
Test
Effects on the ex~perimentally infected mice: -
ICR male mlce of 4 weeks age (10 mice per~one group)
~were used. A prescribed amount of the pathogenic bacteria
:~ , .
suspended in~5 ~,' mucin was lnoculated intraperitoneally. One
hour after the inoculation, the antibiotics as~ mentioned in
the ~ollowing table were administered subcutaneously, and ~;~
; ~hen-the inhibitory effects thereof were measured. The re- ~ - =
sults are shown in the following table. 1~;
.
!:
;
1"'-~
` ' ~',:
''" "
. . ,
- 1~ - ., '
'''''' ' ' ''' ' ' ,
~,......... .
~"' ' ''' '' ,

Table 6 ~ 75g
_ _ . ~ , .,
ED~o m~/mouse ~
, _
Micro- Cbalenge Calbeni- ¦
or~anisms dose Cillin ~ lcefa~olin Calbeni-
inoculated (cell~/mouse) Cef~lzol nl c 1 n
Escherich~a . ::
c~ strain ~.6 X 105 1.12 1.60 3.85 :
_ _ ~ . . . . _
Proteus 1.2 :C 108 ¦ 0.60 ¦ 0~90 ¦ 1.11 -~
~train-5~26 j
. . . ..
C trob traln~ 8.1 X 10 ¦ 12.~ l > 20 ¦ .
815 ~
. Citrobact~r , .
spp., strainl 4.8 X 104 3.28 7 11 > 20
. .
,; .
As made clear from the above results, the synergistic : -
i~hibitory activity of carbeniclllin sodium and cefazolin ~as .
also confirmed by in vivo test~ . v . . :~
-~ Test 4
Synergistic activity of cefazolin and cloxacillin
against pathogen isolated from milk of cow su~fereing from
.
ma~titis in the inhibitory concentration test in ~vitro:
.
In the same manner as described in Test 5, the test
. wa~ oarried out with Serratia epp., strain 22 being resistant ;~
to cephalosporins and penicillins and Staph~lococcus aureus~ .-
~train 7 originated bovine mastitisO The results are shown
ir the followina table-. ~
`.
. .

. _
r
.' . I
; .

37~9
Table_7 (Serratia spp., ~train 22)
Clo~acillin
( ~COgO/n`'l ) _ _
l ~ ~ , . ~
200 + + _ _ _ _ ~ _
_ _ ~ I _.
100 ~. + ~ I - ! -
__ _ _ __
5 + ~ + I + I _ _ _ _ ~
I _ ~ ~ ~
25 + + I ~ + l + +
__ ~
~2.5 rL ¦ + ¦ + + + ¦ Lr
_ _ __ __
6.~5 + ¦ + + rL ~Lr ¦ -Lr ¦ + ¦ _ ¦ .
~ ~ ~ I _ . ~ ,
o~r ~lL~rL ¦ ~ ¦ + ~ ~ ¦ + +
------ - ~ - - ~ --
0 . 6.2512.5 25 50 100 200 400 . 800
Cefaæolin (mcg/ml)
.. . . ~ . ,
T~ble 8 (Staph~ococcus aureus~ strain 7) ~ :
Cloxacillin
tmcg/ml) , -
0 2 + ~ + I _ _ -~-:
~ . , I _~ - ,_ - .' .-
- C).l + 1 + 1 + ~ + I .
: ~ :
0-05 + ¦ -Lr ¦ + ~ ~
.~ ~ . _. ~ ~ ~ __ I I `'
- 0.025 + ¦ ~ ¦ + ¦ ~rL + I +
~ ~ - -t - t-- I - -------r- l :
. - O ' + I + I + I t + I
0, 0.025 0.05 0.1 0.2 0.4 ..
- Cefazolin (mcg/ml)
- ~ est 5 '
The synergistlc activity of FR-10123 and flucloxacil- .
lin against Serratia spp,, ~train 22 isolated from bovine mastitis ~-
was tested in the same manner as described in Test 1, wherein
the pathogen wa~ lnoculated in the medium in a concen~ration of
105 cells/ml. The result3 are shown in the following Table.
, - 12 - -
., ~

7S~
Table 9 (S~E~ 5p~. 9 ~train 22)
Flucloxacillin
(mcg/ml~ ~ _ I
200 ~ ~ _
100 ~=_ = .,
~0 ~ ~
~ _ I I .,
I +_ I + _l + I + I + ~ ~ ~
12 5 + + I + l ~ l + l +
i ,
6.25 + ~ I + I ~ + I + I ~
~ __ _ _ j I ,
o .+ + l + l ~ + l + + l ~ ~ + .
_~ ~ _................ ;
~: 0 6.25 12.5 25 50 100 200 400 800 : :
~R-10123 (mcg~ml)
Tes~ 6 .
- The syner~istic activity o~ FR-10675 and amo~ycil-
lin against Sta~hvlococcus aureus, strain ~ isolated from mil~
o~ ~ow suffering from mastitis was tested in the same manner -~
~ . . - ,
as described in ~`est 1, wherein the pathogen was inoculated in ~ ~:
: the medium in a concentration o~ 106 cells/.ml. The results are .
: : shown in the following Table.
Table 10: (5ta~hvl-ococcus auIeus~ strain 8)
Amoxycillin :
(mcg/ml)
- 6.25 _ _ 3
.13 ~ + + _ _
.56 _ ~ + +
0c78 + + + + . . .
0.39 + + ~ ~. .
_ _
O +. ~ + + .-~ - .
,. _ ._ . ...
g 0.1 0.2 0.39
' FR-10675 (mcg/ml) .. ~ :
The antibact~rial compo3ition~ of the present in- :
~entlon are illu~trated by the follouing ~xample.
: 3

il7S9 ~ ~
- Exam~le 1
Cefnzolin sodium 100 m~
Cloxacillin 100 mg
~anette llax SX (tradename) 50 mg
Soft paraffin 100 mg
Brilliant b~ue ~CF 25 mg :;
~h~ above ingredients were mixed ~ith liquid paraf-
fin to give a total weight of 3 g per infusion preparation.
xample 2
Cefazolin sodium 40 mg .~:
Clo~acillin 150 mg ¦ ;
~anette Wa~ SX (tradename) 50 mg~
- Soft paraffin 100 mg
rilliant blue ~C~ 25~mg
- ~he above ingredients were mi~ed with liquid paraf~
~, :fin to give a total weight of 3 g per infu~ion preparation.
,,
~. ,
: ' - '
'
.
: - 14 -
~" :''''''' '''T
.",

Representative Drawing

Sorry, the representative drawing for patent document number 1038759 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: Expired (old Act Patent) latest possible expiry date 1995-09-19
Grant by Issuance 1978-09-19

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
FUJISAWA PHARMACEUTICAL CO.
Past Owners on Record
MINORU NISHIDA
TOSHIAKI KAMIMURA
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Cover Page 1994-05-17 1 25
Claims 1994-05-17 4 163
Abstract 1994-05-17 1 30
Drawings 1994-05-17 1 17
Descriptions 1994-05-17 13 528